A particularly important aspect of the clinical phenotype of the patients with a PALB2 defect described in this study is that both affected individuals developed B cell non-Hodgkin lymphoma (B-NHL). This evidence concerns the gene PALB2 and B-cell non-Hodgkin lymphoma.